When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

LOS ANGELES -- Tenecteplase (TNKase) is a more powerful thrombolytic for large vessel acute ischemic stroke than alteplase (Activase) but just as safe, the EXTEND-IA TNK trial showed. Tenecteplase ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

Please provide your email address to receive an email when new articles are posted on . Treatment with tenecteplase in an Australian mobile stroke unit was safe and resulted in improved outcomes ...

LOS ANGELES — Not only is tenecteplase a cheaper and more convenient thrombolytic agent than alteplase, but new research suggests it also leads to better outcomes in stroke patients selected for ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase seems to ...